From April 1, 2024 to April 18, 2024, the company has repurchased 2,711,312 shares, representing 0.58% for CLP 42.66 million. With this, the company has completed the repurchase of 6,181,212 shares, representing 1.32% for CLP 100 million under the buyback announced on February 19, 2024.
Vcanbio Cell & Gene Engineering Corp., Ltd
Equities
600645
CNE000000545
Medical Equipment, Supplies & Distribution
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
18.56 CNY | +0.71% | -8.03% | -8.44% |
1st Jan change | Capi. | |
---|---|---|
-8.44% | 1.18B | |
-4.67% | 12.33B | |
-5.19% | 8.14B | |
+28.50% | 5.62B | |
-8.09% | 4.24B | |
-55.31% | 3.06B | |
+13.49% | 2.76B | |
-1.34% | 2.41B | |
+32.24% | 2.23B | |
-3.55% | 1.87B |
- Stock Market
- Equities
- 600645 Stock
- News Vcanbio Cell & Gene Engineering Corp., Ltd
- Tranche Update on Vcanbio Cell & Gene Engineering Corp., Ltd's Equity Buyback Plan announced on February 19, 2024.